Tenofovir alafenamide (TAF) is a novel anti-hepatitis B virus nucleotide analog that can cause dyslipidemia in AIDS patients, although its effect on blood lipids in chronic hepatitis B (CHB) patients is uncertain. For a study, researchers sought to determine how TAF affected blood lipid levels in patients with CHB. About 121 CHB patients were recruited for the TAF group, which included 69 medication-naive patients and 52 individuals who had previously received nucleoside/nucleotide analog therapy. For 48 weeks, all patients were closely monitored. The levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG), as well as the incidence of dyslipidemia, were compared before and after TAF therapy. 

TAF therapy resulted in substantially greater levels of TC, TG, and LDL-C in the TAF group than in the control group after 48 weeks. The TC and TG levels in the TAF group were considerably higher than at baseline. The occurrence of aberrant TC and TG levels after 48 weeks of therapy was significantly affected by baseline TC and TG levels. LDL-C levels fell marginally but not considerably. The proportion of patients with TC abnormalities increased from 20.7% at baseline to 26.3% at week 48, while the proportion of patients with LDL-C abnormalities decreased from 50.4% to 42.5% and the proportion of patients with TG abnormalities increased from 14.2% to 22.5%. There were no significant changes as compared to the control group or the baseline. In individuals with CHB, tenofovir alafenamide therapy mostly impacted TC and TG levels but had minimal effect on LDL-C.